Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer

Nanomedicine

Volumn 9, Issue 7, 2014, Pages 971-987

  Wittig, Rainer ^a   Rosenholm, Jessica M ^b   Von Haartman, Eva ^b   Hemming, Jarl ^b   Genze, Felicitas ^a   Bergman, Lotta ^a   Simmet, Thomas ^a   Lindén, Mika ^a   Sahlgren, Cecilia ^b,c,d  

^a UNIVERSITY OF ULM   (Germany)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

chorioallantoic membrane; folic acid receptor; mesoporous silica nanoparticle; Notch signaling; targeted cancer therapy

Indexed keywords

FOLATE RECEPTOR; FOLIC ACID; GAMMA SECRETASE INHIBITOR; MESOPOROUS SILICA NANOPARTICLE; NANOCARRIER; POLYETHYLENEIMINE; SILICON DIOXIDE; UNCLASSIFIED DRUG; 2,4,6-MESITYLENESULFONYL-3-NITRO-1,2,4-TRIAZOLIDE; DRUG CARRIER; ENZYME INHIBITOR; NANOPARTICLE; SECRETASE; TRIAZINE DERIVATIVE;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER MODEL; CELL TRANSPORT; CHORIOALLANTOIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EVALUATION STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MEMBRANE MODEL; NANOMEDICINE; NANOPHARMACEUTICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SURFACE PROPERTY; TREATMENT OUTCOME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; FEMALE; MOUSE; NUDE MOUSE; POROSITY;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BREAST NEOPLASMS; DRUG CARRIERS; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; POROSITY; SILICON DIOXIDE; TRIAZINES;

EID: 84903845475     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.62     Document Type: Article

References (55)

1. Hearty S, Leonard P, O'Kennedy R. Nanomedicine: barcodes check out prostate cancer. Nat. Nanotechnol. 5(1), 9-10 (2010).
2. Ranganathan R, Madanmohan S, Kesavan A et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int. J. Nanomed. 7, 1043-1060 (2012).
3. Schroeder A, Heller DA, Winslow MM et al. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 12(1), 39-50 (2012).
4. Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomed. (Lond.) 7(4), 597-615 (2012).
5. Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit. Rev. Biomed. Eng. 40(1), 21-41 (2012).
6. Wang J, Lu Z, Gao Y, Wientjes MG, Au JL. Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomed. (Lond.) 6(9), 1605-1620 (2011).
7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007). (Pubitemid 350223348)
8. Gary-Bobo M, Hocine O, Brevet D et al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int. J. Pharm. 423(2), 509-515 (2012).
9. Gary-Bobo M, Mir Y, Rouxel C et al. Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: drug delivery, one and two-photon photodynamic therapy. Int. J. Pharm. 432(1-2), 99-104 (2012).
10. Mamaeva V, Rosenholm JM, Bate-Eya LT et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol. Ther. 19(8), 1538-1546 (2011).
11. Mamaeva V, Sahlgren C, Linden M. Mesoporous silica nanoparticles in medicine - recent advances. Adv. Drug Del. Rev. 65(5), 689-702 (2013).
12. Gary-Bobo M, Mir Y, Rouxel C et al. Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors. Angew Chem. Int. Ed. Engl. 50(48), 11425-11429 (2011).
13. Youns M, Hoheisel JD, Efferth T. Therapeutic and diagnostic applications of nanoparticles. Curr. Drug Targets 12(3), 357-365 (2011).
14. Rosenholm JM, Mamaeva V, Sahlgren C, Linden M. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. Nanomed. (Lond.) 7(1), 111-120 (2012).
15. Hebner C, Weaver VM, Debnath J. Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. Ann. Rev. Path. 3, 313-339 (2008). (Pubitemid 351488284)
16. Friedrich J, Ebner R, Kunz-Schughart LA. Experimental anti-tumor therapy in 3-D: spheroids - old hat or new challenge? Int. J. Radiat. Biol. 83(11-12), 849-871 (2007). (Pubitemid 350219104)
17. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17(3), 320-329 (2011).
18. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 22, 287-309 (2006).
19. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7(1), 17-23 (2005). (Pubitemid 40126379)
20. Rosenholm JM, Peuhu E, Eriksson JE, Sahlgren C, Linden M. Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems. Nano Lett. 9(9), 3308-3311 (2009).
21. Rosenholm JM, Peuhu E, Bate-Eya LT, Eriksson JE, Sahlgren C, Linden M. Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. Small 6(11), 1234-1241 (2010).
22. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 727, 305-319 (2012).
23. Li JL, Jubb AM, Harris AL. Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7), 1099-1103 (2010).
24. Yan M, Callahan CA, Beyer JC et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 463(7282), e6-e7 (2010).
25. van Es JH, van Gijn ME, Riccio O et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435(7044), 959-963 (2005). (Pubitemid 40896322)
26. Wong GT, Manfra D, Poulet FM et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279(13), 12876-12882 (2004).
27. Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25(1), 55-71 (2008).
28. Vargas A, Zeisser-Labouebe M, Lange N, Gurny R, Delie F. The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv. Drug Del. Rev. 59(11), 1162-1176 (2007).
29. Deryugina EI, Quigley JP. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem. Cell Biol. 130(6), 1119-1130 (2008).
30. Kunzi-Rapp K, Genze F, Kufer R, Reich E, Hautmann RE, Gschwend JE. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J. Urology 166(4), 1502-1507 (2001).
31. Ribatti D, Nico B, Mangieri D et al. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol. Histopathol. 22(3), 285-289 (2007). (Pubitemid 46117114)
32. Vogler M, Walczak H, Stadel D et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 69(6), 2425-2434 (2009).
33. Vogler M, Walczak H, Stadel D et al. Targeting XIAP bypasses BCL-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 68(19), 7956-7965 (2008).
34. Wittig-Blaich SM, Kacprzyk LA, Eismann T et al. Matrix-dependent regulation of AKT in hepsin-overexpressing PC3 prostate cancer cells. Neoplasia 13(7), 579-589 (2011).
35. Rosenholm JM, Meinander A, Peuhu E et al. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 3(1), 197-206 (2009).
36. Rosenholm JM, Penninkangas A, Linden M. Amino-functionalization of large-pore mesoscopically ordered silica by a one-step hyperbranching polymerization of a surface-grown polyethyleneimine. Chem. Commun. (Camb.) 37, 3909-3911 (2006). (Pubitemid 44423465)
37. Rosenholm JM, Linden M. Wet-chemical analysis of surface concentration of accessible groups on different amino-functionalized mesoporous SBA-15 silicas. Chem. Mat. 19(20), 5023-5034 (2007). (Pubitemid 47583006)
38. Schneckenburger H, Weber P, Wagner M et al. Light exposure and cell viability in fluorescence microscopy. J. Microscopy 245(3), 311-318 (2012).
39. Rizzo P, Miao H, D'Souza G et al. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68(13), 5226-5235 (2008).
40. Landor SK, Mutvei AP, Mamaeva V et al. Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. Proc. Natl Acad. Sci. USA 108(46), 18814-18819 (2011).
41. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl Acad. Sci. USA 105(17), 6392-6397 (2008). (Pubitemid 351758356)
42. Stylianou S, Clarke RB, Brennan K. Aberrant activation of Notch signaling in human breast cancer. Cancer Res. 66(3), 1517-1525 (2006). (Pubitemid 43259933)
43. Hattori Y, Maitani Y. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther. 12(10), 796-809 (2005). (Pubitemid 43086281)
44. Bin Hafeez B, Adhami VM Asim M et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin. Cancer Res. 15(2), 452-459 (2009).
45. Zeisser-Labouebe M, Delie F, Gurny R, Lange N. Screening of nanoparticulate delivery systems for the photodetection of cancer in a simple and cost-effective model. Nanomed. (Lond.) 4(2), 135-143 (2009).
46. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185-198 (2012).
47. Mahmood M, Casciano D, Xu Y, Biris AS. Engineered nanostructural materials for application in cancer biology and medicine. J. Appl. Toxicol. 32(1), 10-19 (2012).
48. Katsogiannou M, Peng L, Catapano CV, Rocchi P. Active-targeted nanotherapy strategies for prostate cancer. Curr. Cancer Drug Targets 11(8), 954-965 (2011).
49. von Maltzahn G, Park JH, Lin KY et al. Nanoparticles that communicate in vivo to amplify tumor targeting. Nat. Mater. 10(7), 545-552 (2011).
50. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188(6), 759-768 (2010).
51. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349), 377-380 (1998). (Pubitemid 28063372)
52. Olafsen T, Gu Z, Sherman MA et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J. Immunother. 30(4), 396-405 (2007).
53. Kelly KA, Setlur SR, Ross R et al. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res. 68(7), 2286-2291 (2008). (Pubitemid 351521802)
54. Taylor RM, Severns V, Brown DC, Bisoffi M, Sillerud LO. Prostate cancer targeting motifs: expression of alphanu beta3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. Prostate 72(5), 523-532 (2012).
55. Denmeade SR, Mhaka AM, Rosen DM et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci. Transl. Med. 4(140), 140ra86 (2012).